ArticleJournal of Cancer2020
Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer.
Article in Journal of Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.Gynecologic oncology · 2024Trial
- ER, PR, and HER2 triple positivity and triple negativity are associated with adverse prognostic significance in endometrial serous carcinoma.Virchows Archiv : an international journal of pathology · 2026Article
- Differential expression of estrogen and progesterone receptors before and after surgery in endometrial cancer and analysis of recurrence prediction model.World journal of surgical oncology · 2026Article
- Expression of estrogen receptor and progesterone receptor in endometrial cancer and their correlations with clinicopathological features.Frontiers in oncology · 2026Article
- Estrogen-Induced Nesfatin-1 Expression Modulates Endometrial Decidualization in Mice.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Noninvasive Detection and Thermal Ablation Therapy of Endometriosis Using Silica-Coated Gold Nanorods.Advanced nanobiomed research · 2025Article
- Endometrial Carcinoma and Associated Secondary Neoplasia: The Role of Clinical Features, Pathology, and Comorbidities in a University-Affiliated Clinical Center from Western Romania.Medicina (Kaunas, Lithuania) · 2025Article
- An MRI-based radiomics nomogram to predict progression-free survival in patients with endometrial cancer.Future oncology (London, England) · 2025Article
- The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.Protein & cell · 2025Review
- 17β-Hydroxysteroid dehydrogenase type I and aromatase in ovarian cortical inclusion cysts.Endocrine connections · 2025Article
- Immunohistochemical Diversity of Endometrial Carcinoma and Their Implications in Prognosis: A Prospective Clinicopathological Study in a Tertiary Care Hospital of Eastern India.Journal of obstetrics and gynaecology of India · 2025Article
- A brief review of Lynch syndrome: understanding the dual cancer risk between endometrial and colorectal cancer.Oncology reviews · 2025Review
- Drug discovery in advanced and recurrent endometrial cancer: Recent advances.Oncology research · 2025Review
- Divergent ERα co-factor landscapes in gynecological cancers: implications for disease progression and therapy.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2025Review
- The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.British journal of cancer · 2024Article
- Correlation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer.European journal of obstetrics & gynecology and reproductive biology: X · 2024Article
- Review
- Estrogen Receptor (ER) and Progesterone Receptor (PgR) Expression in Endometrial Cancer-An Immunohistochemical Assessment.Diagnostics (Basel, Switzerland) · 2024Article
- Sex-specific outcomes in cancer therapy: the central role of hormones.Frontiers in medical technology · 2024Review
- Utility of ER, p53, CEA and Napsin A in Histological Subtyping of Endometrial Carcinoma and Their Correlation with Clinicopathological Prognostic Parameters: Experience from a Referral Institute.Iranian journal of pathology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.